var title_f29_12_29888="Prayer sign in diabetes";
var content_f29_12_29888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contractures in the metacarpophalangeal joints in diabetes mellitus: Prayer sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positive prayer sign (with waxy skin on the dorsal surface of the fingers) in a patient with diabetes (left panel) and a negative prayer sign in a normal subject (right panel). Contractures in the metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints prevent the hands from being flattened together.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29888=[""].join("\n");
var outline_f29_12_29888=null;
var title_f29_12_29889="LVH M mode echo";
var content_f29_12_29889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M mode echocardiogram recorded within the left ventricle, just below the level of the mitral valve annulus. Concentric left ventricular hypertrophy is seen as both the left ventricular septum and posterior left ventricular wall are significantly thickened, measuring almost 3 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29889=[""].join("\n");
var outline_f29_12_29889=null;
var title_f29_12_29890="AECOPD abx outpatient";
var content_f29_12_29890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Outpatient management of acute exacerbations of COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 565px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Pseudomonas risk factors:",
"     <br>",
"      &nbsp;&nbsp;- Frequent administration of antibiotics (4 or more courses over the past year)",
"      <br>",
"       &nbsp;&nbsp;- Recent hospitalization (2 or more days' duration in the past 90 days)",
"       <br>",
"        &nbsp;&nbsp;- Isolation of Pseudomonas during a previous hospitalization",
"        <br>",
"         &nbsp;&nbsp;- Severe underlying COPD (FEV1 &lt;50 percent predicted)",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sethi, S, Murphy, TF. Acute exacerbations of chronic bronchitis: New developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infect Dis Clin N Am 2004; 18:861. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2004 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29890=[""].join("\n");
var outline_f29_12_29890=null;
var title_f29_12_29891="Absent or irregular periods";
var content_f29_12_29891=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Absent or irregular periods (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/12/29891/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29891/contributors\" id=\"au6052\">",
"       Corrine K Welt, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/12/29891/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29891/contributors\" id=\"se3550\">",
"       William F Crowley, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/12/29891/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29891/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?29/12/29891?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Menstrual cycle disorders can cause a woman's periods to be absent or infrequent. Although some women do not mind missing their menstrual period, these changes should always be discussed with a healthcare provider because they can signal underlying medical conditions and potentially have long-term health consequences. A woman who misses more than three menstrual periods (either consecutively or over the course of a year) should see a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Amenorrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Amenorrhea refers to the absence of menstrual periods, and is classified as either:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Primary (when menstrual periods have not started by age 15)",
"      </li>",
"      <li>",
"       Secondary (when menstrual periods are absent for more than three to six months in a woman who previously had periods)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Oligomenorrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oligomenorrhea is the medical term for infrequent menstrual periods (fewer than six to eight periods per year).",
"    </p>",
"    <p>",
"     The causes, evaluation, and treatment of amenorrhea and oligomenorrhea are similar and will be discussed together.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CAUSES OF IRREGULAR PERIODS",
"     </span>",
"    </p>",
"    <p>",
"     The brain (including the hypothalamus and pituitary gland), ovaries, and uterus normally follow a sequence of events once per month that helps to prepare the body for pregnancy (",
"     <a class=\"graphic graphic_figure graphicRef79496 \" href=\"UTD.htm?13/13/13530\">",
"      figure 1",
"     </a>",
"     ). Two hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH), are made by the pituitary gland. Two other hormones, progesterone and estrogen, are made by the ovaries.",
"    </p>",
"    <p>",
"     Menstrual cycle disorders can result from conditions that affect the hypothalamus, pituitary gland, ovaries, uterus, cervix, or vagina.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Primary amenorrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the more common causes of primary amenorrhea include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Conditions that are present at birth, but may not be noticed until puberty. These conditions include genetic or chromosomal abnormalities and abnormalities of the reproductive organs (eg, if the uterus is not present or developed abnormally).",
"      </li>",
"      <li>",
"       All of the conditions that lead to secondary amenorrhea can also cause primary amenorrhea.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Secondary amenorrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregnancy is the most common of secondary amenorrhea. Other common causes include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Ovarian conditions, such as polycystic ovary syndrome and ovarian insufficiency (early menopause).",
"      </li>",
"      <li>",
"       Hypothalamic amenorrhea. This occurs when the hypothalamus slows or stops releasing GnRH (gonadotropin releasing hormone), a hormone that influences when a woman has a menstrual period.",
"       <br/>",
"       <br/>",
"       Hypothalamic amenorrhea is associated with low body weight (defined as weighing 10 percent below ideal body weight) (",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       ), a low percentage of body fat, eating disorders such as anorexia nervosa or bulimia nervosa, emotional stress, strenuous exercise, and some medical conditions or illnesses. However, in some cases, there is no obvious explanation for hypothalamic amenorrhea.",
"      </li>",
"      <li>",
"       Prolactin-secreting pituitary tumors are another common cause of secondary amenorrhea. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"        \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Oligomenorrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many of the conditions that cause primary or secondary amenorrhea can also cause a woman to ovulate irregularly (oligomenorrhea). However, most women who develop infrequent periods have polycystic ovary syndrome (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Polycystic ovary syndrome'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      EVALUATION OF IRREGULAR PERIODS",
"     </span>",
"    </p>",
"    <p>",
"     The evaluation of",
"     <span class=\"nowrap\">",
"      amenorrhea/oligomenorrhea",
"     </span>",
"     includes a complete medical history and physical examination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      History",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are often clues about the cause of amenorrhea in a woman's personal and family medical history. A woman should mention if she had any health problems during infancy or childhood, when her first period started (if there was a first period) and how frequently periods have occurred since. If known, the woman should also mention if there is any family history of irregular menstrual periods.",
"    </p>",
"    <p>",
"     Other important points include the presence of discharge from the breasts, hot flashes, adult acne, facial or chest hair, and headaches or impaired vision. The clinician will also ask about any medications, herbs, and vitamins used, recent stress, recent gynecologic procedures, changes in weight, diet, or exercise patterns, and illnesses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;During the physical examination, the provider will examine the face, neck, breasts, and abdomen. A pelvic examination will also be performed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Depending upon the individual, the clinician may order blood tests. Because pregnancy is the most common cause of secondary amenorrhea, a pregnancy test is usually recommended for women whose menstrual periods have stopped. Blood tests to measure hormone levels will also be ordered.",
"    </p>",
"    <p>",
"     In selected cases, a magnetic resonance imaging (MRI) test may be done to determine if there are hypothalamic or pituitary gland abnormalities in the brain (",
"     <a class=\"graphic graphic_figure graphicRef63094 \" href=\"UTD.htm?18/19/18739\">",
"      figure 2",
"     </a>",
"     ). Occasionally, in women with a suspected chromosomal abnormality, a chromosome analysis may be recommended. A pelvic ultrasound may be recommended to identify abnormalities of the uterus, cervix, and vagina.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TREATMENT OF IRREGULAR PERIODS",
"     </span>",
"    </p>",
"    <p>",
"     The goal of treatment is to correct the underlying condition. For a woman who is trying to become pregnant, restoring fertility may be another goal. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Polycystic ovary syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is a chronic condition that causes infrequent periods and an excess of androgens (male hormones). Most healthcare providers recommend treating PCOS to reestablish normal menstrual cycles and prevent long-term complications. PCOS is discussed in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Hypothalamic amenorrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with hypothalamic amenorrhea are sometimes able to resume normal menstrual periods after making certain lifestyle changes, such as eating a higher-calorie diet, gaining weight, reducing the intensity or frequency of exercise, and reducing emotional stress.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Low body weight",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       nutritional deficiencies &mdash; Women with eating disorders such as anorexia nervosa or bulimia often need specialized care. This usually includes nutrition counseling and work with eating disorder specialists.",
"      </li>",
"      <li>",
"       Strenuous exercise &mdash; Although exercise offers many health benefits, exercising frequently or excessively can lead to amenorrhea. Studies suggest that amenorrhea develops when a woman's caloric intake is less than she burns with exercise and other daily activities. Most women with amenorrhea associated with exercise have also lost weight (resulting in a weight less than 10 percent of the ideal body weight) (",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For women with exercise-associated amenorrhea, treatments include increasing calorie intake and reducing the frequency",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     intensity of exercise. These measures are particularly important if a woman is trying to become pregnant. All women with amenorrhea should be sure to consume 1200 to 1500 mg of calcium daily (or take a calcium supplement) and a vitamin D supplement (400 int. units daily). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some clinicians recommend estrogen and progestin hormone replacement (or a hormonal contraceptive, such as a birth control pill) for women with hypothalamic amenorrhea. These treatments can reduce the risk of developing osteoporosis later in life. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1124346396\">",
"     <span class=\"h2\">",
"      Ovarian failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Normally, a woman stops ovulating around the age of 50; this is called menopause. If a woman stops ovulating before age 40, this is called premature ovarian failure (or primary ovarian insufficiency). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"      \"Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Being diagnosed with ovarian failure is usually unexpected and can be distressing, especially if the woman has not completed childbearing. In these situations, counseling with a social worker or psychotherapist may be of benefit. With most types of ovarian failure, pregnancy can be achieved using injectable fertility medications and donor eggs. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"      \"Oocyte donation for assisted reproduction\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Although ovarian failure cannot be cured, hormone therapy (HT) with estrogen and progesterone (or a hormonal contraceptive, such as a birth control pill) can help prevent or treat many of the symptoms and long-term consequences of menopause, such as hot flashes, vaginal dryness, and osteoporosis. HT has risks of its own in older women. However, a young (20- to 50-year-old) woman who takes HT does not have the same risks as a &ge;50-year-old woman who takes HT. Current practice is to provide hormone therapy for women with premature ovarian failure until age 50, the average age of menopause.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      High prolactin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with amenorrhea and hyperprolactinemia can usually have normal menstrual periods and become pregnant when treated with medications called dopamine agonists (bromocriptine and cabergoline are examples). This is discussed in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"      \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1124346339\">",
"     <span class=\"h2\">",
"      Hypothalamic or pituitary conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some hypothalamic and pituitary gland conditions that cause amenorrhea, such as a congenital deficiency of gonadotropin-releasing hormone (GnRH), are irreversible. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"      \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, women with these conditions can have menstrual periods and become pregnant when treated with injectable fertility medications. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Endometrial adhesions (Asherman syndrome)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some gynecologic procedures, such as a dilatation and curettage (D&amp;C), can cause adhesions (a type of scar tissue), which damage the uterine lining. If adhesions are extensive, menstrual blood loss will be reduced or absent. A clinician may recommend surgery to remove the scarred tissue, followed by estrogen treatment to stimulate regrowth of the lining. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      \"Patient information: Dilation and curettage (D and C) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1124346294\">",
"     <span class=\"h2\">",
"      Anatomic problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is often an effective treatment if amenorrhea is caused by a blockage in the reproductive tract. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"      \"Diagnosis and management of congenital anomalies of the vagina\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784978098\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11443720\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=see_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11443757\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Hormone Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.hormone.org\">",
"        www.hormone.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/12/29891/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?29/12/29891?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29891/abstract/1\">",
"      Laufer MR, Floor AE, Parsons KE, et al. Hormone testing in women with adult-onset amenorrhea. Gynecol Obstet Invest 1995; 40:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29891/abstract/2\">",
"      Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998; 83:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29891/abstract/3\">",
"      Loucks AB, Vaitukaitis J, Cameron JL, et al. The reproductive system and exercise in women. Med Sci Sports Exerc 1992; 24:S288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29891/abstract/4\">",
"      Warren MP, Voussoughian F, Geer EB, et al. Functional hypothalamic amenorrhea: hypoleptinemia and disordered eating. J Clin Endocrinol Metab 1999; 84:873.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_12_29891=[""].join("\n");
var outline_f29_12_29891=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CAUSES OF IRREGULAR PERIODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           EVALUATION OF IRREGULAR PERIODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TREATMENT OF IRREGULAR PERIODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/13/13530\" title=\"figure 1\">",
"           Menstrual cycle PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/19/18739\" title=\"figure 2\">",
"           Brain pituitary anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_12_29892="Dermatofibroma - shin";
var content_f29_12_29892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatofibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This firm, hyperpigmented papule on the shin is a dermatofibroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29892=[""].join("\n");
var outline_f29_12_29892=null;
var title_f29_12_29893="Rufinamide: Pediatric drug information";
var content_f29_12_29893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rufinamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/30/5606?source=see_link\">",
"    see \"Rufinamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18517?source=see_link\">",
"    see \"Rufinamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6802947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Banzel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13245578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Banzel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F7989953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Triazole Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F7989965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/30/5606?source=see_link\">",
"      see \"Rufinamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Lennox-Gastaut syndrome:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;4 years: Initial: 10 mg/kg/day in 2 equally divided doses; increase dose by ~10 mg/kg increments every other day to a target dose of 45 mg/kg/day in 2 equally divided doses (maximum dose: 3200 mg/day); effectiveness of doses lower than the target dose is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Initial: 400-800 mg/day in 2 equally divided doses; increase dose by 400-800 mg/day every other day to a maximum dose of  3200 mg/day in 2 equally divided doses; effectiveness of doses lower than 3200 mg/day is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant medications:",
"     </b>",
"     Valproate: Initial rufinamide dose should be &lt;10 mg/kg/day (children) or 400 mg/day (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis: No specific guidelines available; consider dosage adjustment for loss of drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild to moderate impairment: Use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe impairment: Use in severe impairment has not been studied and is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6819489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banzel&reg;: 40 mg/mL (460 mL) [dye free, gluten free; contains propylene glycol; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banzel&reg;: 200 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6819386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088564.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088564.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7989966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: May be swallowed whole, split in half, or crushed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Shake well; use provided adapter and calibrated oral syringe to measure dose.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7989962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect tablets from moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Discard within 90 days after opening; cap of bottle fits over the adapter.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7989954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (FDA approved in ages &ge;4 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6819402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: QT shortening (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Aggression, anxiety, ataxia, attention disturbance, dizziness, fatigue, headache, hyperactivity, seizure, somnolence, status epilepticus, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased/increased, constipation, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia. leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Back pain, gait disturbance, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Pollakiuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory:  Bronchitis, nasopharyngitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Atrioventricular block (first degree), bundle branch block (right), dysuria, enuresis, hematuria; hypersensitivity (multiorgan; includes eosinophilia, facial edema, fever, hepatitis [severe], LFTs increased, rash, stupor, urticaria); incontinence, iron-deficiency anemia, lymphadenopathy, nephrolithiasis, neutropenia, nocturia, polyuria, thrombocytopenia, urinary incontinence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7989957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rufinamide or any component; patients with familial short QT syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F11822970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild to moderate hepatic impairment; use is not recommended in patients with severe hepatic impairment. May cause leukopenia. Concomitant use with valproic acid may increase rufinamide serum concentrations; rufinamide dosage adjustment recommended. Children may experience some adverse effects not reported in adults, including aggression, attention disturbance, hyperactivity, pruritus, rash, nasopharyngitis, and seizures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Suspension contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use rufinamide suspension containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7989958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Central nervous system adverse events including somnolence, fatigue, coordination abnormalities, dizziness, gait disturbances, and ataxia may occur; effects with other sedative drugs or ethanol may be potentiated; patients should be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Avoid abrupt discontinuation of therapy; withdraw gradually (~25% dose reduction every 2 days) to lessen chance for increased seizure frequency; if abrupt discontinuation is medically necessary, close medical supervision is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially serious, sometimes fatal, multiorgan hypersensitivity reactions (including severe hepatitis) have been reported with some antiepileptic drugs, including rufinamide; cases reported with rufinamide occurred in children &lt;12 years and presented within the first 4 weeks of therapy. Monitor for rash, fever, and signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems. Patients who develop rash should be closely monitored for other signs and symptoms of reaction; if hypersensitivity reaction(s) is suspected; discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Shortening of the QT interval has been reported; in a placebo-controlled QT interval study, ECG findings showed 46% to 65% of rufinamide-treated patients experienced a possible dose-dependent QT shortening of &gt;20 msec at the time of maximum serum concentrations compared to 5% to 10% of placebo patients; however, QT interval reductions did not fall below 300 msec and no signs of ventricular arrhythmias or sudden death reported. Do not use in patients with familial short QT syndrome and use with caution in patients receiving concurrent medications that shorten the QT interval.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Rufinamide. Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving divalproex. In patients receiving rufinamide, initiate divalproex at a low dose and titrate based on clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethinyl Estradiol: Rufinamide may decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norethindrone: Rufinamide may decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Rufinamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Rufinamide. Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7989961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases the extent of absorption by 34% and peak exposure by 56%; it is recommended to take doses with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6819391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6819392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were seen in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed. Hormonal contraceptives may be less effective with concurrent rufinamide use; additional forms of nonhormonal contraceptives should be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to rufinamide during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7989967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency, duration, and severity; CBC; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes); consider ECG (with concurrent medications that can shorten QT interval)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7989963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A triazole-derivative antiepileptic whose exact mechanism is unknown.",
"     <i>",
"      In vitro",
"     </i>",
"     , it prolongs the inactive state of the sodium channels, thereby limiting repetitive firing of sodium-dependent action potentials mediating anticonvulsant effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7989964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic data in pediatric patients (4-17 years) has been shown to be similar to adult data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Slow; extensive &ge;85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Apparent V",
"     <sub>",
"      d",
"     </sub>",
"     : ~50 L (dose-dependent, dose: 3200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 34%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively via carboxylesterase-mediated hydrolysis of the carboxylamide group to CGP 47292 (inactive metabolite); weak inhibitor of CYP2E1 and weak inducer of CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Extent decreased with increased dose; oral tablets and oral suspension are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: ~6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine [85%, ~66% as CGP 47292 (inactive metabolite), &lt;2% as unchanged drug]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Decreased AUC by 30% and maximum serum concentration by 16%; consider dosage adjustment",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7989968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18517?source=see_link\">",
"      see \"Rufinamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of rufinamide. Take exactly as prescribed with food. Avoid alcohol. May cause drowsiness and impair ability to perform activities requiring mental alertness and physical coordination. Do not discontinue abruptly (an increase in seizure activity may result). Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm. May cause headache, fatigue, nausea, and/or vomiting (small, frequent meals, frequent oral care, sucking lozenges, or chewing gum may help). Report fever associated with rash, swelling, or other organ system involvement immediately to physician. Report worsening of seizure activity or loss of seizure control. Hormonal contraceptives may be less effective if used with this medication. Another form of nonhormonal contraceptive should be used.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 40 mg/mL oral suspension may be made using tablets. Crush twelve 400 mg tablets (or twenty-four 200 mg tablets) and reduce to a fine powder. Add 60 mL of Ora-Plus&reg; in incremental proportions until a smooth suspension is obtained; then mix well while adding 60 mL of Ora-Sweet&reg; or Ora-Sweet&reg; SF; transfer to a calibrated bottle. Label \"shake well\". Stable 90 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Hutchinson DJ, Liou Y, Best R, et al, \"Stability of Extemporaneously Prepared Rufinamide Oral Suspensions,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2010, 44(3):462-5.",
"     <span class=\"pubmed-id\">",
"      20150505",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/12/29893/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser T, Kluger G, Sachdeo R, et al, &ldquo;Rufinamide for Generalized Seizures Associated With Lennox-Gastaut Syndrome,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2008, 70(21):1950-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/12/29893/abstract-text/18401024/pubmed\" id=\"18401024\" target=\"_blank\">",
"        18401024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16777 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29893=[""].join("\n");
var outline_f29_12_29893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802947\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13245578\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989953\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989965\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819489\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819386\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874987\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989966\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989962\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989954\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819402\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989957\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822970\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989958\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300017\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833946\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989961\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819391\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6819392\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989967\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989963\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989964\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7989968\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806484\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16777\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16777|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/30/5606?source=related_link\">",
"      Rufinamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/5/18517?source=related_link\">",
"      Rufinamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_12_29894="Prednisolone (systemic): Patient drug information";
var content_f29_12_29894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Prednisolone (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40376?source=see_link\">",
"     see \"Prednisolone (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/54/1896?source=see_link\">",
"     see \"Prednisolone (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flo-Pred&trade;;",
"     </li>",
"     <li>",
"      Millipred&trade;;",
"     </li>",
"     <li>",
"      Millipred&trade; DP;",
"     </li>",
"     <li>",
"      Orapred ODT&reg;;",
"     </li>",
"     <li>",
"      Orapred&reg;;",
"     </li>",
"     <li>",
"      Pediapred&reg;;",
"     </li>",
"     <li>",
"      Veripred&trade; 20",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hydeltra T.B.A.&reg;;",
"     </li>",
"     <li>",
"      Novo-Prednisolone;",
"     </li>",
"     <li>",
"      Pediapred&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat COPD (chronic obstructive pulmonary disease).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling from autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling in parts of the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prednisolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet (Orapred ODT&trade;):",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully. Use the measuring device that comes with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12298 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-BB2650B2D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29894=[""].join("\n");
var outline_f29_12_29894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024507\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024509\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024508\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024513\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024514\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024516\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024511\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024512\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024517\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024518\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/0/30723?source=related_link\">",
"      Prednisolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/13/43220?source=related_link\">",
"      Prednisolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37650?source=related_link\">",
"      Prednisolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40376?source=related_link\">",
"      Prednisolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/54/1896?source=related_link\">",
"      Prednisolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_12_29895="Intermediate case 4 with answer";
var content_f29_12_29895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wolff-Parkinson-White pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Precordial leads in a patient with preexcitation due to the WPW syndrome. The three characteristic findings are the short PR interval (0.09 sec in this case), the wide QRS, and the delta wave (slurring of the QRS upstroke) that is best seen in leads V5 and V6 (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29895=[""].join("\n");
var outline_f29_12_29895=null;
var title_f29_12_29896="Unusual fungal infections in the neonate";
var content_f29_12_29896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unusual fungal infections in the neonate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/12/29896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29896/contributors\">",
"     Mohan Pammi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/12/29896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29896/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/12/29896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29896/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/12/29896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections, other than those caused by Candida species, are uncommon in neonates. These are often overlooked because neonatal infections due to bacteria, viruses, and Candida are more prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonetheless, noncandidal fungal infections occur in neonates resulting in significant mortality and morbidity. They include aspergillosis, cutaneous and intestinal zygomycosis, malessezia sepsis, trichosporonosis, pichia sepsis, cryptococcosis, coccidioidomycosis, blastomycosis, and dermatophytosis.",
"   </p>",
"   <p>",
"    Similar to Candida infections, the incidence of noncandidal fungal infections in neonates appears to be increasing, particularly in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2\">",
"     2",
"    </a>",
"    ]. Premature infants may be more vulnerable to fungal infections because of their immature immune system, poorly developed epithelial skin and mucosal barriers, and the high rate of invasive procedures, such as central venous catheters and intubation, which compromise host defenses (eg, skin integrity). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noncandidal fungal infections in the neonate and their treatment will be reviewed here. The epidemiology, clinical manifestations, treatment and prevention of neonatal Candida infection are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=see_link\">",
"     \"Overview of Candida infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link\">",
"     \"Treatment of candidemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEONATAL FUNGAL INFECTIONS OTHER THAN CANDIDA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspergillus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus species are ubiquitous molds commonly found in air, soil, decaying vegetation, and dust. Infections are most commonly caused by A. fumigatus, A. flavus, and A. niger. Mortality is very high in infected neonates, even when treated with antifungal therapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reports of neonatal Aspergillus infection appear to be increasing. In a review of the literature from 2002, 16 of the 17 cases of primary cutaneous aspergillosis were published after 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for neonatal aspergillosis include gestational age below 32 weeks, birth weight below 1500 g, and new construction or hospital renovations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, hospital gauze, bedding, tape, and dressing are vehicles for transmission of Aspergillus spores [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The administration of broad-spectrum parenteral antibiotics and corticosteroids are also strongly associated with disseminated aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, primary infection generally involves either the skin or respiratory tract. Rapid systemic dissemination may occur resulting in significant mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous &mdash; Premature infants are at increased risk for primary cutaneous aspergillosis because their skin is thin and delicate. Typically, the skin lesion begins as an erythematous patch or a plaque that rapidly progresses to hemorrhagic bullae. Within 24 hours, the lesion subsequently develops into purpuric ulcerations and black eschar formation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2\">",
"       2",
"      </a>",
"      ]. Lesions generally form on the back or other dependent areas.",
"     </li>",
"     <li>",
"      Respiratory &mdash; Respiratory involvement occurs with inhalation of Aspergillus spores resulting in pneumonia.",
"     </li>",
"     <li>",
"      Disseminated disease &mdash; Respiratory failure, liver failure, seizures, and skin lesions are reported features of disseminated aspergillosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2,6\">",
"       2,6",
"      </a>",
"      ]. The organism also has a propensity to invade blood vessels, causing thrombosis, infarction, and necrosis. Hemorrhagic necrosis is frequently seen in the lung and gastrointestinal tract in autopsies of affected patients. Rare manifestations of disseminated disease include meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/7\">",
"       7",
"      </a>",
"      ] and obstructive renal aspergilloma in a neonate with bladder exstrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of aspergillosis can be made by demonstrating Aspergillus by microscopic examination or culture of tissue obtained by biopsy or from body fluids. Polymerase chain reaction (PCR) may be useful in detecting Aspergillus species in cerebral spinal fluid (CSF) or serum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspergillus must be distinguished from other fungi including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida can be distinguished from Aspergillus because the hyphae of Candida are smaller and do not branch.",
"     </li>",
"     <li>",
"      Zygomycetes can be distinguished from Aspergillus by their larger size, irregularity, and absence of septa.",
"     </li>",
"     <li>",
"      Penicillium is the most difficult species to differentiate from Aspergillus, but its hyphae are generally broader and contain fewer septa than Aspergillus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Zygomycosis (mucormycosis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy over the terminology used to refer to infections due to this class of fungi. The older, and more common, term \"mucormycosis\" is familiar to most clinicians. However, zygomycosis has become the preferred term since other members of this class of fungi can cause infection, in addition to those in the order Mucorales.",
"   </p>",
"   <p>",
"    Although Zygomycetes fungi are uncommon causes of neonatal infections, there are several reports of infections in newborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. Infections are due to organisms from the genera Rhizopus, Mucor, and Absidia.",
"   </p>",
"   <p>",
"    Risk factors for neonatal zygomycosis include prematurity, low birth weight, use of broad-spectrum antibiotics and corticosteroids, and local skin trauma due to vascular catheters and adhesive dressings. Transmission of the fungi may be due to contact with contaminated surfaces such as adhesive tape or dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one report, four cases of Rhizopus microsporus in premature infants were due to contaminated wooden tongue depressors used as splints to secure intravenous and arterial cannulation sites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical presentations of neonatal zygomycosis include primary cutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/12\">",
"     12",
"    </a>",
"    ] or gastrointestinal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/10,11,13,14\">",
"     10,11,13,14",
"    </a>",
"    ]. Gastrointestinal disease resembles necrotizing enterocolitis but without the radiological changes, and is associated with a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/10,13,19\">",
"     10,13,19",
"    </a>",
"    ]. Vascular invasion is the hallmark of zygomycosis and is often associated with vascular thrombosis and tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis relies upon the identification of organisms in tissue by histopathology with culture confirmation. However, the organism often does not grow in culture, and histopathological identification of a zygomycete may provide the only evidence of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy consists of local debridement or surgical resection, and the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/11-13,21,22\">",
"     11-13,21,22",
"    </a>",
"    ]. Maintaining skin integrity by avoiding trauma to the skin by insertion of catheters and dressings, as much as possible, is the best approach to prevent primary cutaneous infection. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Amphotericin B'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malassezia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1981, the first case of a neonatal infection with a Malassezia species was reported in a preterm infant receiving intralipid emulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/23\">",
"     23",
"    </a>",
"    ]. Subsequently, several other cases were reported of Malassezia infections in premature and low birth weight infants.",
"   </p>",
"   <p>",
"    Malassezia mainly colonizes the skin and, occasionally, the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Neonatal infections are caused by one of four species; Malassezia furfur, pachydermatis, globus, and sympodialis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/24\">",
"     24",
"    </a>",
"    ]. All Malassezia species except M. pachydermatis require exogenous long chain fatty acids for growth. This requirement may explain the associated risk of this infection in infants who receive intralipid emulsions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for Malassezia colonization and infection include prematurity, increased length of stay in a neonatal intensive care unit (NICU), administration of intralipid emulsions, central venous catheters, skin emollients, and the administration of broad-spectrum antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of neonatal Malessezia fungemia are nonspecific and include apnea, bradycardia, fever, respiratory distress, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, thrombus and thromboembolism are reported complications from catheter-related fungemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malassezia infections including the diagnosis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6021?source=see_link\">",
"     \"Malassezia infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dermatophytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatophytes refer to the classes of fungi that cause the most common type of fungal skin and nail infections in healthy older patients commonly referred to as \"ringworm\". Three types of superficial",
"    <span class=\"nowrap\">",
"     fungi/dermatophytes",
"    </span>",
"    account for the majority of these infections: Epidermophyton, Trichophyton, and Microsporum.",
"   </p>",
"   <p>",
"    In neonates, tinea facei, tinea capitis, tinea corporis, and extensive skin lesions have been reported due to Microsporum infections as isolated case reports, and in one reported outbreak in a newborn nursery due to transmitted infection by a health care worker [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Kerion Celsi is an inflammatory response to dermatophyte infection and has been reported in three neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/35\">",
"     35",
"    </a>",
"    ]. Topical antifungal agents may be used in neonates with superficial infection. However, in cases with suspected disseminated disease, systemic antifungal therapy should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trichosporon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichosporon species are rare fungi that may cause superficial infections of hair shafts in the head, axilla, and the genital area. Nodules of about 0.5 mm, referred to as white piedras, are attached to the hair shafts. In a review of the literature published in 2000, 12 cases of neonatal Trichosporon infections were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/36\">",
"     36",
"    </a>",
"    ]. Possible risk factors included prematurity, low birth weight (birth weight below 1500 g), and the use of systemic antibiotics.",
"   </p>",
"   <p>",
"    In immunocompromised hosts including premature infants, disseminated and often fatal infections usually occur. Although most neonates have disseminated disease (approximately 70 percent), there are reports of isolated urinary tract infection and colonization of a central venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case report from one NICU in 1991, a cluster of four cases occurred over a two month time period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/37\">",
"     37",
"    </a>",
"    ]. Three patients were very low birth weight infants with gestational age 23 to 25 weeks, two of whom died. The fourth was a full term infant with respiratory distress and a femoral central venous catheter.",
"   </p>",
"   <p>",
"    Trichosporon species have been identified in genital cultures in women, which makes vertical transmission a possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Respiratory or the gastrointestinal tract may act as portals of entry into the systemic circulation resulting in disseminated disease.",
"   </p>",
"   <p>",
"    Trichosporon infections including the diagnosis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1785?source=see_link\">",
"     \"Infections due to Trichosporon species and Blastoschizomyces capitatus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cryptococcal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal infection in neonates is rare with few reported cases reports of meningitis and disseminated fungemia due to Cryptococcus neoformans and laurenti [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In infants, dissemination of the organism results in multisystem involvement of the brain, meninges, eyes, liver, and spleen. It is invariably a fatal infection without therapy. The diagnosis is made by visualization of the organism by India ink staining of affected body fluids, or detection of cryptococcal antigen in body fluids, such as cerebrospinal fluid (CSF) or respiratory secretions. Positive culture results from blood, CSF, sputum, or urine specimens confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coccidioidomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reported neonatal cases of coccidioidomycosis, which generally have presented with severe pulmonary disease with systemic dissemination resulting in multisystem involvement including the brain and meninges [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2\">",
"     2",
"    </a>",
"    ]. C. immitis is the only known Coccidioidomycosis species and is thought to be transmitted to the infant during delivery with the neonatal aspiration of infectious vaginal secretion. There is, however, one case of an infant who developed neonatal coccidioidomycosis and was delivered by cesarean delivery suggesting in utero transplacental vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis can be made by identification of the organism by microscopic examination of respiratory secretions or tissues, or by a positive culture of the CSF, urine, or sputum, or serologic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blastomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare fatal case reports of neonatal blastomycosis have been reported that presented with pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/44\">",
"     44",
"    </a>",
"    ]. Similar to other neonatal fungal infections, the mode of transmission of the infection is thought to be from an infected mother to her offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/2,44\">",
"     2,44",
"    </a>",
"    ]. Diagnosis is by microscopic visualization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture the organism from respiratory secretions and tissues. The validity of serological tests for diagnosis is not known in neonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of blastomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pichia infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pichia anomala (formerly known as Hansenula anomala) is a yeast of the class ascomycetes. It has been the cause of reported both isolated cases and nosocomial outbreaks of infections in NICUs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. Risk factors associated with P. anomala infections include prematurity, low birth weight, central venous catheter, broad-spectrum antibiotics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    with lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Outbreaks of infections have been due to nosocomial transmission of the organism from carriers who were health care workers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the reported outbreaks, 52 infants (10 percent of the infants in the NICU) were colonized with the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/45\">",
"     45",
"    </a>",
"    ]. Eight premature infants became infected, of which all but one were heavily colonized before infection. Seven of the infants had disseminated fungemia, and two had CNS involvement. One patient only had CNS infection without fungemia.",
"   </p>",
"   <p>",
"    Neonatal infections due to other Pichia species have also been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pichia fabianii is an uncommon yeast species that has been noted in two case series [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Molecular diagnostic methods are required to identify the species [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kodea (Pichia) ohmeri infections have been reported in premature neonates and are associated with significant mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/52-54\">",
"       52-54",
"      </a>",
"      ]. Diagnosis is made by biochemical and molecular methods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with noncandidal invasive fungal infection have a high risk of mortality. As a result, systemic antifungal agents should be administered to any infant who is suspected of having a serious fungal infection. The mainstay of therapy for neonatal invasive fungal infection is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . Other antifungal agents that have been used, primarily in infants with candidal infections, include triazoles (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    ), adjunctive nucleoside analogues (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    ), and echinocandins.",
"   </p>",
"   <p>",
"    In case reports, combination antifungal therapy has been successful in the treatment of serious and often fatal unusual fungemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, the clinician's choice of therapy is dictated by the available information regarding the extent and outcome of infection by the specific fungi, and the clinical condition of the patient.",
"   </p>",
"   <p>",
"    In our practice,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is used as the initial therapy. Other agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) are added if there is central nervous system involvement, if the response to initial therapy is slow especially in a critically ill patient, or to reduce the dose of amphotericin B during ongoing treatment in a patient who has responded to initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been demonstrated in vitro against a wide variety of clinical fungal isolates, including Candida spp., Coccidioides immitis, Aspergillus spp., Histoplasma capsulatum, Blastomyces dermatitidis, Cryptococcus neoformans, and Sporothrix schenckii. Amphotericin B exerts its antifungal effect by disruption of fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized control trials demonstrating the efficacy of this agent in treating neonates with invasive noncandidal fungal infections. However, several cases have been reported of survival in neonates treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with infections that are usually considered to be fatal if left untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/4,12,16,21,40,41,45\">",
"     4,12,16,21,40,41,45",
"    </a>",
"    ]. Hence, amphotericin B remains the first choice of treatment in neonates suspected of having an invasive fungal infection",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is only available in parenteral form. Pharmacokinetic data demonstrate achievement of therapeutic plasma levels with administered dosing regimens between 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, although there is patient variability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Excellent blood and tissue levels of amphotericin are achieved with the above dosing regimen. However, the penetration into the cerebral spinal fluid (CSF) of neonates is variable, ranging from 40 to 90 percent of plasma levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/57\">",
"     57",
"    </a>",
"    ]. As a result, most experts do not recommend amphotericin B as the sole drug to treat central nervous system (CNS) neonatal fungal infections. In these patients,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    should be added to amphotericin, because both agents penetrate the CSF well and are synergistic to amphotericin B.",
"   </p>",
"   <p>",
"    Similar to treatment of invasive candidal infection, the duration of therapy is uncertain. Most neonatologists and pediatric infectious disease specialists treat for a minimum of 14 days after sterilization of the infected body fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18151921\">",
"    <span class=\"h3\">",
"     Amphotericin b lipid formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-based",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations have the ability to deliver a higher dose of medication with lower levels of toxicity, but are significantly more expensive than standard amphotericin B. Although case reports have shown that they are effective in treating coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/59\">",
"     59",
"    </a>",
"    ] and Trichosporon infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/60\">",
"     60",
"    </a>",
"    ], they are typically reserved for neonates who develop intolerant infusion-related reactions or renal dysfunction during standard amphotericin B administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of Candida infection in neonates\", section on 'Amphotericin B lipid formulations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of amphotericin appear to be less common in neonates than in older children and adults. Although there is a potential for nephrotoxicity, most infants display no or only mild nephrotoxicity, which resolves with decreasing the dose of the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/61\">",
"     61",
"    </a>",
"    ]. Other reported adverse effects include hypokalemia and hypomagnesemia caused by excessive renal losses, bone marrow suppression with anemia and thrombocytopenia, and an increase in hepatic enzymes. These abnormalities are infrequent, dose dependent, and resolve with cessation of the drug.",
"   </p>",
"   <p>",
"    Because of the potential adverse effects, infants should have serial monitoring of serum potassium, magnesium and creatinine, liver enzymes, and complete blood count while receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triazoles are antifungal agents that inhibit the 14-alpha-sterol demethylase of the cytochrome P450 system, which is necessary for the production of ergosterol, a major component of the fungal cell membrane.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is the most commonly used triazole in neonatal practice.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is available in both intravenous and oral preparations. Both of these formulations result in wide tissue penetration including the CSF and ocular fluid. Fluconazole has been used alone or in conjunction with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in the treatment of neonatal cryptococcosis, coccidioidomycosis, and candidiasis. It has also been used as an alternate therapy in the treatment of histoplasmosis, blastomycosis, and sporotrichosis.",
"   </p>",
"   <p>",
"    Pharmacokinetic data indicate that a longer dosing interval is required for neonates because",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    is renally excreted, and the neonate has a low glomerular filtration rate (GFR). The dosing interval decreases with increasing postnatal age as GFR rises [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than two weeks of age &mdash; 6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose given every 72 hours",
"     </li>",
"     <li>",
"      Two to four weeks of age &mdash; 6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose given every 48 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other triazoles include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/59/6074?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"     voriconazole",
"    </a>",
"    , but their use has been limited in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, the most commonly used nucleoside analogue is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    , a fluorine analogue of cytosine. It inhibits thymidylate synthetase, thereby disrupting DNA synthesis. It has a narrow spectrum of activity and has been shown to be effective in the treatment of candidal and cryptococcal infection.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    as a sole agent is limited because of the rapid development of resistance when used as monotherapy. It is mainly used in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in neonates with candidal and cryptococcal meningitis, because flucytosine has excellent penetration into the CSF and is synergistic with amphotericin B.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"     Flucytosine",
"    </a>",
"    is only available in enteral form, thus limiting its use in critically ill neonates. The oral dose is 50 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into four doses at six hour intervals. Serum levels of flucytosine should be monitored to avoid reversible bone marrow suppression, which has been associated with serum levels &gt;100",
"    <span class=\"nowrap\">",
"     &micro;g/ml",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29896/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins prevent the formation of glucan polymers, a major component of the fungal cell wall, by inhibiting the 1,3-beta-D-glucan synthase enzyme complex. These agents appear to be well-tolerated with minimal adverse effects, because this enzymatic complex is not found in mammals. Resistance to this class of antifungal agents is uncommon.",
"   </p>",
"   <p>",
"    Echinocandins include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/29/9686?source=see_link\">",
"     micafungin",
"    </a>",
"    , which have all been shown to be effective and safe in adult patients. In neonates, data are limited primarily to treating patients with candidal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of Candida infection in neonates\", section on 'Echinocandins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungal infections, other than those caused by Candida species, are uncommon in neonates, however, when they occur, these infections result in significant neonatal mortality and morbidity. Noncandidal fungal infections include aspergillosis, cutaneous and intestinal zygomycosis, malessezia sepsis, trichosporonosis, pichia sepsis, cryptococcosis, coccidioidomycosis, blastomycosis and dermatophytosis.",
"     </li>",
"     <li>",
"      The incidence of these infections is increasing particularly in premature infants. Other associated risk factors for fungemia in addition to prematurity include the administration of broad-spectrum antimicrobial agents, use of immunosuppressive therapy (eg, corticosteroids), invasive procedures (eg, central venous catheters), and in some cases new hospital construction or renovations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neonatal fungal infections other than candida'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants with known or suspected fungemia or central nervous system (CNS) infection require immediate systemic antifungal therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neonatal fungal infections other than candida'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"       \"Treatment of Candida infection in neonates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      as the preferred initial therapy in neonates with fungemia or with suspected fungemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternate therapy includes",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      as monotherapy or in combination with amphotericin B. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with or suspected to have noncandidal CNS infections, we suggest treatment with a combination therapy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/46/27365?source=see_link\">",
"       flucytosine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternate therapy includes combination therapy of amphotericin B and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/1\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     Maldonado, YA. Pneumocystis and other less common fungal infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th, Remington, JS, et al. (Eds), Elsevier Saunders, Philadelphia 2010. p.1078.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/3\">",
"      Woodruff CA, Hebert AA. Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol 2002; 19:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/4\">",
"      Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/5\">",
"      Roth JG, Troy JL, Esterly NB. Multiple cutaneous ulcers in a premature neonate. Pediatr Dermatol 1991; 8:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/6\">",
"      Roncati L, Barbolini G, Fano RA, Rivasi F. Fatal Aspergillus flavus infection in a neonate. Fetal Pediatr Pathol 2010; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/7\">",
"      Phute SU, Bhakre JB. Aspergillus fumigatus Meningitis in a Preterm. Indian Pediatr 2010; 47:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/8\">",
"      Martinez-Pajares JD, Martinez-Ferriz MC, Moreno-Perez D, et al. Management of obstructive renal failure caused by bilateral renal aspergilloma in an immunocompetent newborn. J Med Microbiol 2010; 59:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/9\">",
"      Hummel M, Spiess B, Roder J, et al. Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. J Med Microbiol 2009; 58:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/10\">",
"      Agarwal K, Sharma M, Singh S, Jain M. Antemortem diagnosis of gastrointestinal mucormycosis in neonates: report of two cases and review of literature. Indian J Pathol Microbiol 2006; 49:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/11\">",
"      Alexander P, Alladi A, Correa M, D'Cruz AJ. Neonatal colonic mucormycosis--a tropical perspective. J Trop Pediatr 2005; 51:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/12\">",
"      Oh D, Notrica D. Primary cutaneous mucormycosis in infants and neonates: case report and review of the literature. J Pediatr Surg 2002; 37:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/13\">",
"      Diven SC, Angel CA, Hawkins HK, et al. Intestinal zygomycosis due to Absidia corymbifera mimicking necrotizing enterocolitis in a preterm neonate. J Perinatol 2004; 24:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/14\">",
"      Nichol PF, Corliss RF, Rajpal S, et al. Perforation of the appendix from intestinal mucormycosis in a neonate. J Pediatr Surg 2004; 39:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/15\">",
"      Roilides E, Zaoutis TE, Walsh TJ. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2009; 15 Suppl 5:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/16\">",
"      Linder N, Keller N, Huri C, et al. Primary cutaneous mucormycosis in a premature infant: case report and review of the literature. Am J Perinatol 1998; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/17\">",
"      White CB, Barcia PJ, Bass JW. Neonatal zygomycotic necrotizing cellulitis. Pediatrics 1986; 78:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/18\">",
"      Mitchell SJ, Gray J, Morgan ME, et al. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 1996; 348:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/19\">",
"      Veleminsky M Sr, Noll P, Hanzl M, Veleminsky M Jr. Necrotizing enterocolitis in children with low birth-weight induced with mucormycose strains. Neuro Endocrinol Lett 2008; 29:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/20\">",
"      Dennis JE, Rhodes KH, Cooney DR, Roberts GD. Nosocomical Rhizopus infection (zygomycosis) in children. J Pediatr 1980; 96:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/21\">",
"      Morales-Aguirre JJ, Ag&uuml;ero-Echeverr&iacute;a WM, Ornelas-Carsolio ME, et al. Successful treatment of a primary cutaneous zygomycosis caused by Absidia corymbifera in a premature newborn. Pediatr Infect Dis J 2004; 23:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/22\">",
"      Siu KL, Lee WH. A rare cause of intestinal perforation in an extreme low birth weight infant--gastrointestinal mucormycosis: a case report. J Perinatol 2004; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/23\">",
"      Redline RW, Dahms BB. Malassezia pulmonary vasculitis in an infant on long-term Intralipid therapy. N Engl J Med 1981; 305:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/24\">",
"      Zomorodain K, Mirhendi H, Tarazooie B, et al. Molecular analysis of Malassezia species isolated from hospitalized neonates. Pediatr Dermatol 2008; 25:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/25\">",
"      Ayhan M, Sancak B, Karaduman A, et al. Colonization of neonate skin by Malassezia species: relationship with neonatal cephalic pustulosis. J Am Acad Dermatol 2007; 57:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/26\">",
"      Aschner JL, Punsalang A Jr, Maniscalco WM, Menegus MA. Percutaneous central venous catheter colonization with Malassezia furfur: incidence and clinical significance. Pediatrics 1987; 80:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/27\">",
"      Richet HM, McNeil MM, Edwards MC, Jarvis WR. Cluster of Malassezia furfur pulmonary infections in infants in a neonatal intensive-care unit. J Clin Microbiol 1989; 27:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/28\">",
"      Marcon MJ, Powell DA. Epidemiology, diagnosis, and management of Malassezia furfur systemic infection. Diagn Microbiol Infect Dis 1987; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/29\">",
"      Kessler AT, Kourtis AP, Simon N. Peripheral thromboembolism associated with Malassezia furfur sepsis. Pediatr Infect Dis J 2002; 21:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/30\">",
"      Jacobs AH, Jacobs PH, Moore N. Tinea facei due to Microsporum canis in an eight-day-old infant. JAMA 1972; 219:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/31\">",
"      Drusin LM, Ross BG, Rhodes KH, et al. Nosocomial ringworm in a neonatal intensive care unit: a nurse and her cat. Infect Control Hosp Epidemiol 2000; 21:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/32\">",
"      Kamalam A, Thambiah AS. Tinea facei caused by Microsporum gypseum in a two days old infant. Mykosen 1981; 24:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/33\">",
"      Metkar A, Joshi A, Vishalakshi V, et al. Extensive neonatal dermatophytoses. Pediatr Dermatol 2010; 27:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/34\">",
"      Sproul AV, Whitehall J, Engler C. Trichophyton tonsurans-Ringworm in an NICU. Neonatal Netw 2009; 28:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/35\">",
"      Larralde M, Gomar B, Boggio P, et al. Neonatal kerion Celsi: report of three cases. Pediatr Dermatol 2010; 27:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/36\">",
"      Salazar GE, Campbell JR. Trichosporonosis, an unusual fungal infection in neonates. Pediatr Infect Dis J 2002; 21:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/37\">",
"      Fisher DJ, Christy C, Spafford P, et al. Neonatal Trichosporon beigelii infection: report of a cluster of cases in a neonatal intensive care unit. Pediatr Infect Dis J 1993; 12:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/38\">",
"      Ellner K, McBride ME, Rosen T, Berman D. Prevalence of Trichosporon beigelii. Colonization of normal perigenital skin. J Med Vet Mycol 1991; 29:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/39\">",
"      Kalter DC, Tschen JA, Cernoch PL, et al. Genital white piedra: epidemiology, microbiology, and therapy. J Am Acad Dermatol 1986; 14:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/40\">",
"      Gavai M, Gaur S, Frenkel LD. Successful treatment of cryptococcosis in a premature neonate. Pediatr Infect Dis J 1995; 14:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/41\">",
"      Cheng MF, Chiou CC, Liu YC, et al. Cryptococcus laurentii fungemia in a premature neonate. J Clin Microbiol 2001; 39:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/42\">",
"      Nakwan N, Ngerncham S, Srisuparp P, et al. Cryptococcus neoformans septicemia in an immunocompetent neonate: first case report in Thailand. Southeast Asian J Trop Med Public Health 2008; 39:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/43\">",
"      Charlton V, Ramsdell K, Sehring S. Intrauterine transmission of coccidioidomycosis. Pediatr Infect Dis J 1999; 18:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/44\">",
"      Watts EA, Gard PD Jr, Tuthill SW. First reported case of intrauterine transmission of blastomycosis. Pediatr Infect Dis 1983; 2:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/45\">",
"      Murphy N, Buchanan CR, Damjanovic V, et al. Infection and colonisation of neonates by Hansenula anomala. Lancet 1986; 1:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/46\">",
"      Arag&atilde;o PA, Oshiro IC, Manrique EI, et al. Pichia anomala outbreak in a nursery: exogenous source? Pediatr Infect Dis J 2001; 20:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/47\">",
"      Chakrabarti A, Singh K, Narang A, et al. Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in Northern India. J Clin Microbiol 2001; 39:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/48\">",
"      Ma JS, Chen PY, Chen CH, Chi CS. Neonatal fungemia caused by Hansenula anomala: a case report. J Microbiol Immunol Infect 2000; 33:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/49\">",
"      Wong AR, Ibrahim H, Van Rostenberghe H, et al. Hansenula anomala infection in a neonate. J Paediatr Child Health 2000; 36:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/50\">",
"      Grenouillet F, Millon L, Chamouine A, et al. Pichia fabianii Fungemia in a Neonate. Pediatr Infect Dis J 2010; 29:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/51\">",
"      Bhally HS, Jain S, Shields C, et al. Infection in a neonate caused by Pichia fabianii: importance of molecular identification. Med Mycol 2006; 44:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/52\">",
"      Taj-Aldeen SJ, Doiphode SH, Han XY. Kodamaea (Pichia) ohmeri fungaemia in a premature neonate. J Med Microbiol 2006; 55:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/53\">",
"      Poojary A, Sapre G. Kodamaea ohmeri infection in a neonate. Indian Pediatr 2009; 46:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/54\">",
"      Sundaram PS, Bijulal S, Tharakan JA, Antony M. Kodamaea ohmeri tricuspid valve endocarditis with right ventricular inflow obstruction in a neonate with structurally normal heart. Ann Pediatr Cardiol 2011; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/55\">",
"      Santos RP, S&aacute;nchez PJ, Mejias A, et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J 2007; 26:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/56\">",
"      Bassetti M, Bisio F, Di Biagio A, et al. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. J Antimicrob Chemother 2004; 54:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/57\">",
"      Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/58\">",
"      Starke JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987; 155:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/59\">",
"      Antony S, Dominguez DC, Sotelo E. Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis. J Natl Med Assoc 2003; 95:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/60\">",
"      Sweet D, Reid M. Disseminated neonatal Trichosporon beigelii infection: successful treatment with liposomal amphotericin B. J Infect 1998; 36:120.",
"     </a>",
"    </li>",
"    <li>",
"     Bendel CM. Candidiasis. In: Infectious diseases of the fetus and newborn infant, 6th, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.1107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/62\">",
"      Sax&eacute;n H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993; 54:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/63\">",
"      Wenzl TG, Schefels J, H&ouml;rnchen H, Skopnik H. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr 1998; 157:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/64\">",
"      Almirante B, Rodr&iacute;guez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007; 9:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29896/abstract/65\">",
"      Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15:1003.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4988 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29896=[""].join("\n");
var outline_f29_12_29896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEONATAL FUNGAL INFECTIONS OTHER THAN CANDIDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspergillus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Zygomycosis (mucormycosis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malassezia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dermatophytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trichosporon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pichia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18151921\">",
"      - Amphotericin b lipid formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Flucytosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1785?source=related_link\">",
"      Infections due to Trichosporon species and Blastoschizomyces capitatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6021?source=related_link\">",
"      Malassezia infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_12_29897="Acrokeratosis verruciformis";
var content_f29_12_29897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86092%7EDERM%2F86093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86092%7EDERM%2F86093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acrokeratosis verruciformis of Hopf",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acrokeratosis verruciformis of Hopf: Palmar pits and punctate keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29897=[""].join("\n");
var outline_f29_12_29897=null;
var title_f29_12_29898="The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries";
var content_f29_12_29898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/12/29898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29898/contributors\">",
"     Emily P Hyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29898/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/12/29898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29898/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/12/29898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/12/29898/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/12/29898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 34 million people are living with HIV, with 2.7 million new HIV infections and 1.8 million AIDS deaths in 2010 alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/1\">",
"     1",
"    </a>",
"    ]. While early mortality was nearly certain in the beginning of the AIDS epidemic, drug discovery and the introduction of combination therapy in 1995 resulted in profound reductions in morbidity and mortality (",
"    <a class=\"graphic graphic_figure graphicRef58099 \" href=\"UTD.htm?4/57/5023\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND EARLY THERAPEUTIC INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prophylaxis against opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of HIV infection begins with a period of clinical latency, despite ongoing viral replication, immune activation, and progressive immunodeficiency. Declining cellular immunity increases the risk of developing opportunistic infections (OIs), particularly when the CD4 T-cell count is &le;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the late 1980s, the mainstay of treatment was prophylaxis for opportunistic infections including Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis, and Mycobacterial avium complex (MAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/3-12\">",
"     3-12",
"    </a>",
"    ]. Survival benefits of PCP and MAC prophylaxis were demonstrated in a computer simulation model of HIV disease using published data and surveys from the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/13\">",
"     13",
"    </a>",
"    ]. Per-person survival benefit was 3.1 months for PCP prophylaxis alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Zidovudine monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1983 discovery of HIV as the etiology of AIDS led to a targeted search for an agent with anti-HIV activity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    was the first medication shown to inhibit HIV replication, and a randomized placebo-controlled trial in 1986 demonstrated that administration of zidovudine decreased mortality and the risk of opportunistic infections in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/14\">",
"     14",
"    </a>",
"    ]. The results of this trial led to the expedited FDA approval of zidovudine by the FDA in 1987.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    also decreased the rate of CD4 decline when prescribed in asymptomatic HIV-infected patients with CD4 &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/15\">",
"     15",
"    </a>",
"    ], but no mortality benefit was seen for these patients with earlier disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Two-drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional antiretroviral medications were soon developed and clinical trials demonstrated that two-drug therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and another nucleoside analog (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    or zalcitabine) slowed the progression of HIV disease and was superior to treatment with zidovudine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This benefit of improved survival was also demonstrated in patients with CD4 cell counts ranging from 200 to 500 CD4",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMBINATION ANTIRETROVIRAL THERAPY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In December 1995, the first protease inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    , was approved by the US Food and Drug Administration (FDA), leading to the advent of potent antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. Combination ART with three active drugs from at least two different mechanistic classes demonstrated sustained viral suppression and dramatic mortality benefit in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Observational and retrospective cohort studies from multiple countries and several continents confirmed the striking improvements in mortality with combination ART compared with earlier one- or two-drug regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By 2006, the use of ART, opportunistic infection (OI) prophylaxis, and the prevention of mother-to-child transmission (PMTCT) in the US alone had contributed to a cumulative survival benefit of nearly three million years for persons with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/13\">",
"     13",
"    </a>",
"    ]. Using clinical trial and cohort data, mathematical models estimate an increased long-term survival of over 20 years for HIV-infected patients on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/28\">",
"     28",
"    </a>",
"    ]. In a study of 6366 patients attending an urban HIV clinic in the United States over 15 years, 87 percent were using ART, and the mortality rate was 2.1 events per 100 person years by 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/29\">",
"     29",
"    </a>",
"    ]. Based on these findings, the life expectancy for a 28-year-old HIV-infected individual in care in 2009 was calculated to be an additional 45.4 years. Notably, a large proportion of the study population were racial minorities, had a history of intravenous drug use, or had public or no health insurance, characteristics typically associated with worse outcomes.",
"   </p>",
"   <p>",
"    Due to an increasing number of medications and drug classes, viral suppression can now be achieved even in heavily pretreated patients with multidrug-resistant virus. The most important period of drug development for these patients occurred from 2005 to 2008, with several drugs approved within a short enough period of time to allow multiple active agents to be used simultaneously &ndash; often for the first time in these patients. The later generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , and protease inhibitors (PIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , retain activity against many resistant viral isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Agents from newer classes of drugs, such as the integrase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    ) and the CCR5 inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    ), have demonstrated efficacy for salvage therapy in patients with extensive drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. The combination of these new agents improves efficacy, even in the most difficult to treat patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the overall rates of morbidity and mortality have declined dramatically among people living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    a substantial proportion of deaths continue to be AIDS-related, particularly among those with lower CD4 cell counts and those presenting late to care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/40\">",
"     40",
"    </a>",
"    ]. Additionally, racial disparities in HIV mortality persist despite an overall decline in mortality rates over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/41\">",
"     41",
"    </a>",
"    ]. Chronic diseases not traditionally thought to be AIDS-related (eg, liver, cardiovascular, cancer, and renal) have also emerged as an important cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the greater availability of more potent, less toxic antiretroviral medications coupled with a better understanding of HIV pathogenesis, HIV treatment guidelines from the United States now recommend ART in all HIV-infected patients, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL THERAPY AND OPPORTUNISTIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given its effect on partial immune recovery, potent antiretroviral therapy (ART) has further reduced the general incidence of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/23\">",
"     23",
"    </a>",
"    ]. In one large retrospective study, the incidence of any of three major opportunistic infections (Pneumocystis jirovecii pneumonia, Mycobacterial avium complex, cytomegalovirus) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/22\">",
"     22",
"    </a>",
"    ]. Randomized controlled trials and cohort studies alike have demonstrated reductions in mortality secondary to AIDS regardless of sex, race, age, and risk factors for HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/22,24,25,29,47\">",
"     22,24,25,29,47",
"    </a>",
"    ]. The effect of ART on reducing the risk of HIV-related opportunistic infections is greater than that provided by opportunistic infection prophylaxis; hence, the urgency of ART is greatest in those with the most advanced HIV-related immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL THERAPY AND COMORBIDITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its mortality benefits, antiretroviral therapy (ART) has decreased noninfectious HIV-associated morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/20,42,45,48,49\">",
"     20,42,45,48,49",
"    </a>",
"    ]. Some studies have demonstrated that among HIV-infected patients with CD4 cell counts of &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    serious non-AIDS events are more common and associated with higher rates of mortality than AIDS-related events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/50\">",
"     50",
"    </a>",
"    ]. Factors that independently predicted death due to non-AIDS events in this report were diabetes, advanced age, and hepatitis",
"    <span class=\"nowrap\">",
"     B/hepatitis",
"    </span>",
"    C status.",
"   </p>",
"   <p>",
"    Chronic ART administration may cause lipid abnormalities, drug-induced liver injury, and renal insufficiency. Lipid abnormalities are most commonly seen with protease-inhibitor based regimens and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    use is most strongly associated with kidney injury, especially in those with other risk factors for renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link&amp;anchor=H14340801#H14340801\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Tenofovir'",
"    </a>",
"    .) Several studies have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    use may be associated with an increased risk of cardiovascular disease; potential mechanisms include a drug-mediated increase in certain inflammatory cytokines (such as CRP) and platelet reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. This adverse cardiovascular effect has not been shown in all studies and uncertainty remains [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link&amp;anchor=H742816#H742816\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Abacavir'",
"    </a>",
"    .) Concerns about nucleoside analog-associated mitochondrial toxicity have declined with the availability of tenofovir and abacavir [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/46,61\">",
"     46,61",
"    </a>",
"    ]. Clinical treatment trials continue to compare alternative combinations of ART to determine the most potent, but least toxic regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Liver-related morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As deaths from AIDS and opportunistic infections (OIs) have declined and people live longer with HIV infection, morbidity related to comorbidities such as viral hepatitis have assumed greater importance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/42\">",
"     42",
"    </a>",
"    ]. HIV-infected patients who are coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV) have an increased risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Chronic HBV or HCV also increases the risk of drug-induced liver injury related to the administration of ART, particularly if aminotransferases are abnormal at baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of viral hepatitis, liver-related mortality among HIV-infected patients on ART is low and comparable to that seen in patients without HIV or HCV infection",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/65\">",
"      65",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HBV",
"    coinfected patients are at risk for accelerated morbidity and mortality. Antiviral treatment active against both infections is strongly recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/66\">",
"     66",
"    </a>",
"    ], and many medications have potent dual activity against HIV and HBV (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Close monitoring for the immune reconstitution syndrome (IRIS) is indicated when initiating ART, given the risk of significant hepatic flares. Conversely, discontinuing antiretroviral agents that have activity against HBV may lead to a rapid rise in liver enzymes and HBV DNA; in some cases this reactivation is associated with severe and life-threatening liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfection, ART is associated with reductions in non-OI-related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/69,70\">",
"     69,70",
"    </a>",
"    ] and possibly slower progression rates of liver fibrosis. Of 10 studies that investigated the effect of ART on the risk of liver disease, half reported a significant protective association [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HIV-associated nephropathy and end-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HIV-associated nephropathy may be related to a combination of factors, including HIV infection itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of ART has been associated with a dramatic decline in the incidence of HIV-associated nephropathy. ART-mediated viral suppression is associated with improvements in glomerular filtration rate in patients with preexisting renal insufficiency and in those with baseline CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/72\">",
"     72",
"    </a>",
"    ]. In a five-year retrospective study of 4000 HIV-infected patients, the risk of nephropathy was 60 percent lower among patients treated with ART; no cases were reported among patients who began ART prior to progression to AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/73\">",
"     73",
"    </a>",
"    ]. The initiation of ART was also associated with a reduced risk of developing end-stage renal disease in a small cohort of 36 patients with biopsy-proven HIV-associated nephropathy (HIVAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain antiretroviral medications are associated with increased risk of hyperlipidemia, which has raised concerns regarding chronic exposure to ART and risk of coronary artery disease.",
"   </p>",
"   <p>",
"    HIV infection itself may accelerate atherosclerosis. In a large trial designed to assess ART-interruption strategies, 2720 patients who were randomly assigned to the treatment interruption arm experienced a higher risk of cardiovascular events compared with 2752 patients on the continuous treatment arm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/75\">",
"     75",
"    </a>",
"    ]. Another study suggested that CD4 counts &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    were an independent risk factor for cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"     \"Structured treatment interruptions in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several causative mechanisms have been proposed, including the presence of proinflammatory cytokines, endothelial damage and dysfunction, and increased hypercoagulability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further research is ongoing to distinguish the independent contributions of HIV infection versus ART use on the development of metabolic syndromes and cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     AIDS-defining malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi's sarcoma (KS), non-Hodgkin lymphoma (NHL), and primary central nervous system lymphoma were recognized early in the AIDS epidemic as aggressive malignancies and were included as AIDS-defining illnesses in the case definitions from the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/78\">",
"     78",
"    </a>",
"    ]. These AIDS-defining malignancies are associated with immunologic decline in untreated HIV infection, although a direct pathogenic role for HIV infection has also been suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the widespread introduction of ART, the incidence of Kaposi's sarcoma and lymphoma has declined, and the clinical outcome of patients with these tumors has improved with restoration of cellular immunity and viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/79\">",
"     79",
"    </a>",
"    ]. However, ART has had little impact on other AIDS-defining malignancies, such as invasive cervical cancer, which continues to occur at higher rates in HIV-infected patients compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Non-AIDS-defining malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to AIDS-defining malignancies, non-AIDS-defining cancers have emerged as a major cause of death in HIV-infected patients in the era of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/42,81\">",
"     42,81",
"    </a>",
"    ]. In a prospective observational cohort of more than 61,000 patients, the incidence of the following hematologic and solid malignancies was significantly higher in the HIV-infected population than in the general population: Hodgkin lymphoma, leukemia, melanoma, and anal, vaginal, liver, lung, colorectal and renal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In fact, in one large study, the incidence of Hodgkin lymphoma and liver cancer increased in later periods of ART (1996 to 2002) compared with earlier time periods (1991 to 1995) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/83\">",
"     83",
"    </a>",
"    ]. Furthermore, these malignancies (eg, lung cancer and hepatocellular carcinoma) generally presented at a younger age, with more advanced disease at diagnosis, and with poorer patient outcomes than in HIV-uninfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although low CD4 cell counts have been found to be a risk factor for non-AIDS-defining malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/85\">",
"     85",
"    </a>",
"    ], the impact of treatment-associated immune reconstitution has not been as dramatic as in AIDS-defining malignancies. Potential explanations for higher cancer rates among HIV-infected patients compared with the general population include longer survival of patients on ART, a high incidence of coinfections with potentially oncogenic viruses (eg, human papillomavirus, Epstein-Barr virus, hepatitis B and C), and a high prevalence of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4926281\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of ART on the incidence and mortality of tuberculosis (TB) in persons with HIV has been well described in resource-limited settings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings\"",
"    </a>",
"    ), but data from resource-rich countries are more sparse. The CDC analyzed cases of culture-positive tuberculosis diagnosed in the United States from 1993 to 2008 with the analysis of incidence and mortality data stratified by HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/87\">",
"     87",
"    </a>",
"    ]. The proportion of all patients with TB who died during treatment decreased from 18 percent (2445 cases) in 1993 to 9 percent (7578 cases) in 2006. The observed decline in the case-fatality rate was mainly represented by those who were also HIV-infected and corresponded to wider HIV testing and broader availability of potent ART during the span of the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COSTS AND COST-EFFECTIVENESS OF ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal cost-effectiveness analyses have incorporated clinical, epidemiologic, and economic data to assess the value of antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/88\">",
"     88",
"    </a>",
"    ]. The lifetime costs of care for patients with HIV infection were estimated to be over $600,000 per person in 2006, which largely comprise outpatient and drug costs; inpatient care now comprises less than 15 percent of the total costs due to the effectiveness of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/28\">",
"     28",
"    </a>",
"    ]. Later generation ART regimens described above will further increase these costs, as they further improve survival. One study suggests that when available, generic versions of first-line antiretrovirals may offer opportunities for substantial cost savings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/89\">",
"     89",
"    </a>",
"    ]. Among the small clinical trade-offs associated with these cost savings will be an increased pill burden (and potential for slight decreases in adherence), because generic-based options are not yet coformulated in the United States.",
"   </p>",
"   <p>",
"    Multiple analyses have repeatedly demonstrated that ART is highly cost effective in the US compared with other types of health care expenditures, despite the increased costs for patients on ART given increases in life-expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/28,90\">",
"     28,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OPTIMIZING THE EFFECTIVENESS OF ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of HIV RNA testing in 1996, treatment decisions were initially made solely based on CD4 thresholds and opportunistic infections as markers for immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/91\">",
"     91",
"    </a>",
"    ]. Subsequently, HIV RNA testing also assumed great importance for determining baseline viremia and confirming viral suppression on treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/92-95\">",
"     92-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New questions have arisen regarding effective utilization of specialized laboratory testing for optimum patient management. Drug resistance testing is integral in the selection of antiretroviral therapy both in treatment-naive and treatment-experienced patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. Viral tropism assays guide the use of CCR5 antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/100\">",
"     100",
"    </a>",
"    ]. Lastly, testing for HLA-B*5701 can be used to decrease the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once viral suppression and immune reconstitution have been stably accomplished on an effective ART regimen, CD4 cell count monitoring can be reduced in frequency as routine monitoring may be of limited utility, particularly for those patients with CD4 cell counts &gt;300",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/46,103,104\">",
"     46,103,104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link&amp;anchor=H9#H9\">",
"     \"Patient monitoring during HIV antiretroviral therapy\", section on 'Frequency of laboratory monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ART AND HIV TRANSMISSION/PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence among specific patient populations and in large population studies that use of antiretroviral agents, either as treatment by the HIV-infected or as prophylaxis by the uninfected, is effective in reducing HIV transmission. Although most of the data are from trials performed in resource-limited settings, the results are applicable to corresponding populations within resource-rich settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevention of mother-to-child transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of antiretroviral therapy (ART) to HIV-infected pregnant women has substantially reduced vertical transmission and has been one of the major successes in HIV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Discordant couples",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART reduces the rate of HIV transmission per contact and plays a vital role in transmission prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/107\">",
"     107",
"    </a>",
"    ]. This observed effect may be mediated by reductions in HIV RNA concentrations in both cervical fluids and semen in patients on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. Mathematical modeling has suggested that rapid roll-out of ART could reduce rates of new HIV infections among high-risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HPTN 052 trial recruited 1763 HIV-1 serodiscordant heterosexual couples at 13 sites in nine countries in Africa, Asia, South America, and North America from 2005 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/111\">",
"     111",
"    </a>",
"    ]. The trial was designed to determine if treatment of the HIV-infected sex partner would decrease the risk of HIV transmission to the uninfected partner. The trial demonstrated that ART, initiated in a CD4 cell count range of 350 to 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    was associated with a 96 percent reduction in HIV transmission to an uninfected sex partner compared with starting ART at a lower CD4 cell count (ie, &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H5769013#H5769013\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Impact of ART on HIV transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Preexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the need for more data to inform the optimal approach, pre-exposure prophylaxis with daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    may be an effective strategy for preventing HIV infection in uninfected patients at high risk of sexual transmission who are committed to medication adherence and close follow-up. Several trials in various high-risk populations, including men who have sex with men, heterosexual individuals with an HIV-infected partner, and heterosexual individuals in areas of high HIV prevalence, have demonstrated a reduction in the risk of HIV infection by 48 to 75 percent with daily use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. A separate trial in African women that did not show efficacy of tenofovir-emtricitabine in reducing the risk of HIV infection may have been substantially limited by nonadherence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/115\">",
"     115",
"    </a>",
"    ]. Pre-exposure with tenofovir-emtricitabine is discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H49825196#H49825196\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H94403822#H94403822\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Approach to pre-exposure prophylaxis against HIV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variable results have been reported with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in a vaginal gel formulation to prevent sexually-acquired HIV infection in women. While one trial demonstrated an overall reduction in HIV infections by 39 percent with pericoital use of tenofovir gel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/117\">",
"     117",
"    </a>",
"    ], a second showed no efficacy with daily use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/118\">",
"     118",
"    </a>",
"    ]. Additional studies are ongoing to further evaluate the efficacy of vaginal chemoprophylaxis against HIV infection. No study data are yet available on the use of tenofovir gel to prevent HIV transmission in resource-rich countries; tenofovir gel is not yet commercially available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H5844460#H5844460\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Vaginal chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost considerations involved in the widespread implementation of pre-exposure prophylaxis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H1252555#H1252555\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Cost considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2256325\">",
"    <span class=\"h2\">",
"     Population studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohort studies and mathematical models have suggested that treatment of a greater percentage of HIV-infected patients, including those who do not meet treatment criteria for their own individual health, could be a potential strategy to reduce HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. Because HIV transmission is proportional to viral load, the impact of ART on viral load reduction in plasma and in other biologic fluids, such as semen and vaginal secretions, would likely have an impact on HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A population-based retrospective study of ART coverage and new HIV diagnoses in British Columbia from 1996 and 2009 found that the number of individuals receiving ART increased from 837 to 5413 (a 547 percent increase) and the number of new HIV diagnoses fell from 702 to 338 per year (a 52 percent decrease) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/122\">",
"     122",
"    </a>",
"    ]. For every 100 additional individuals on ART, the number of new HIV cases decreased by a factor of 0.97 (95% CI 0.96-0.98). Furthermore, for each 1 log decline in viral load, the number of new HIV cases decreased by a factor of 0.86 (95% CI 0.75-0.98).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     UPCOMING CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the known effectiveness of ART and new recommendations to consider ART in all HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/46\">",
"     46",
"    </a>",
"    ], ongoing efforts are increasingly focused on improving engagement in care and successful ART implementation (",
"    <a class=\"graphic graphic_figure graphicRef87058 \" href=\"UTD.htm?40/47/41726\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/106,123\">",
"     106,123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnostic testing and linkage to care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis of HIV infection leads to better patient outcomes and reduces viral transmission to others [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/124\">",
"     124",
"    </a>",
"    ]. Thus, in 2006, the Centers for Disease Control and Prevention recommended routine HIV testing of all adolescents and adults; the cost effectiveness of this approach has been demonstrated in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. Linkage to care is an additional challenge: 20 to 40 percent of newly HIV-diagnosed patients still fail to establish care within six months of diagnosis, despite the known clinical benefit of timely therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/48,127-130\">",
"     48,127-130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Adherence and retention in care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment success also relies on adherence, which has been greatly facilitated by reductions in pill burden, lower dosing frequency, improved toxicity profiles, and enhanced pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. Risk factors associated with poor adherence still include financial instability, reduced social supports, less education, alcohol use, African-American race, complex ART regimens, mental health, and substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/133-135\">",
"     133-135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are lost to follow-up experience worse outcomes than those remaining in care. Approximately one-third of patients who are HIV-infected in the US are not in active care, despite the availability of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/130\">",
"     130",
"    </a>",
"    ]. Additionally, increased mortality rates are associated with missed outpatient appointments in the first year of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/136\">",
"     136",
"    </a>",
"    ]. Retention in active medical care is a distinct challenge that requires targeted interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/12/29898/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While early mortality was nearly certain for most HIV-infected patients in the beginning of the epidemic, the introduction of potent combination therapy has resulted in profound reductions in morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early in the",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      epidemic, the only available therapeutic interventions included prophylaxis against various opportunistic infections and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      monotherapy, which decreased mortality in patients with AIDS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history and early therapeutic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The introduction of combination antiretroviral therapy with three active drugs from at least two different mechanistic classes led to dramatic mortality benefits compared with earlier one or two-drug regimens. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Combination antiretroviral therapy and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The era of potent antiretroviral therapy has been associated with significant declines in morbidity related to AIDS-defining malignancies and in end-stage renal disease. However, antiretroviral therapy has had a less robust impact on non-AIDS-defining malignancies. Viral suppression may also be important in decreasing cardiovascular events, although the administration of antiretroviral therapy has also been associated with adverse lipid profiles. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antiretroviral therapy and comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those with",
"      <span class=\"nowrap\">",
"       HIV/hepatitis",
"      </span>",
"      B virus or",
"      <span class=\"nowrap\">",
"       HIV/hepatitis",
"      </span>",
"      C virus coinfection, antiretroviral treatment is likely to be beneficial in delaying liver fibrosis progression. Patients with chronic viral hepatitis and elevated aminotransferases at baseline need close monitoring. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Liver-related morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although increased life expectancy for patients on antiretroviral therapy leads to increased costs, data support that ART is highly cost effective in the US compared with other accepted health care interventions. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Costs and cost-effectiveness of ART'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy reduces rates of perinatal HIV transmission and transmission between discordant couples. Pre-exposure prophylaxis is an additional strategy that may effectively reduce the risk of HIV infection among high-risk individuals. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'ART and HIV transmission/prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"       \"HIV treatment as prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"       \"Pre-exposure prophylaxis against HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1396806388\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Kenneth A Freedberg MD, MSc and Rochelle P Walensky MD, MPH who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     2011 World Health Organization Progress Report. file://www.who.int/hiv/pub/progress_report2011/en/index.html (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     The Centers for Disease Control and Prevention. AIDS Surveillance - General Epidemiology. 2008. file://www.cdc.gov/hiv/topics/surveillance/resources/slides/epidemiology/index.htm (Accessed on February 27, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/3\">",
"      Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/4\">",
"      Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/5\">",
"      Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/6\">",
"      Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/7\">",
"      El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999; 29:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/8\">",
"      Havlir DV, Dub&eacute; MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/9\">",
"      Havlir DV, Dub&eacute; MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/10\">",
"      Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med 1993; 329:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/11\">",
"      Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/12\">",
"      Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/13\">",
"      Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/14\">",
"      Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/15\">",
"      Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/16\">",
"      Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/17\">",
"      Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996; 348:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/18\">",
"      Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/19\">",
"      Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/20\">",
"      Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/21\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/22\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/23\">",
"      Dore GJ, Li Y, McDonald A, et al. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 2002; 29:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/24\">",
"      Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/25\">",
"      Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/26\">",
"      Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/27\">",
"      Schneider MF, Gange SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005; 19:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/28\">",
"      Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/29\">",
"      Moore RD, Keruly JC, Bartlett JG. Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis 2012; 55:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/30\">",
"      Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/31\">",
"      Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/32\">",
"      Pozniak A, Opravil M, Beatty G, et al. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Res Hum Retroviruses 2008; 24:1275.",
"     </a>",
"    </li>",
"    <li>",
"     Harris M, Larsen G, Montaner JS. Outcomes of patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen (abstract 799). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/34\">",
"      Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339.",
"     </a>",
"    </li>",
"    <li>",
"     Lennox J, Dejesus E, Lazzarin A. STARTMRK, A Phase III study of the safety &amp; efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients (abstract H-896a). 48th International Conference on Antimicrobial Agents and Chemotherapy. 2008. Washington, DC.",
"    </li>",
"    <li>",
"     Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies (abstract 792). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.",
"    </li>",
"    <li>",
"     Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada (abstract 104bLB). 14th Conference on Retroviruses and Opportunistic Infections. 2007. Los Angeles, CA.",
"    </li>",
"    <li>",
"     Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results (abstract 104aLB). 14th Conference on Retroviruses and Opportunistic Infections. 2007. Los Angeles, CA.",
"    </li>",
"    <li>",
"     Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. XVII International AIDS Conference. 2008. Mexico City, Mexico.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/40\">",
"      Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/41\">",
"      Simard EP, Fransua M, Naishadham D, Jemal A. The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med 2012; 172:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/42\">",
"      Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/43\">",
"      Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/44\">",
"      Wada N, Jacobson LP, Cohen M, et al. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/45\">",
"      Masi&aacute; M, Padilla S, &Aacute;lvarez D, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS 2013; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. file://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (Accessed on February 13, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/47\">",
"      Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/48\">",
"      Jain MK, Skiest DJ, Cloud JW, et al. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/49\">",
"      Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/50\">",
"      Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/51\">",
"      Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/52\">",
"      Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/53\">",
"      Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/54\">",
"      Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011; 25:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/55\">",
"      McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/56\">",
"      Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/57\">",
"      Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/58\">",
"      Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/59\">",
"      Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/60\">",
"      Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/61\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/62\">",
"      Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/63\">",
"      MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/64\">",
"      Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/65\">",
"      Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clin Infect Dis 2013; 56:870.",
"     </a>",
"    </li>",
"    <li>",
"     www.aidsinfo.nih.gov/guidelines/ (Accessed on April 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/67\">",
"      Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/68\">",
"      Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/69\">",
"      Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/70\">",
"      Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/71\">",
"      Kramer JR, Giordano TP, El-Serag HB. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol 2007; 5:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/72\">",
"      Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/73\">",
"      Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/74\">",
"      Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/75\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"    <li>",
"     Lichtenstein KA. CD4+ T-cell counts &lt; 350 cells/mm3 are a risk factor for cardiovascular disease in the HIV Outpatient Study (HOPS). XVII International AIDS Conference. 2008. Mexico City, Mexico.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/77\">",
"      Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 49 Suppl 2:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/78\">",
"      1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/79\">",
"      Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/80\">",
"      de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis 2009; 199:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/81\">",
"      Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010; 51:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/82\">",
"      Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/83\">",
"      Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/84\">",
"      Spano JP, Costagliola D, Katlama C, et al. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/85\">",
"      Monforte Ad, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/86\">",
"      Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007; 19:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/87\">",
"      Centers for Disease Control and Prevention (CDC). Mortality among patients with tuberculosis and associations with HIV status --- United States, 1993-2008. MMWR Morb Mortal Wkly Rep 2010; 59:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/88\">",
"      Anis AH, Guh D, Hogg RS, et al. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 2000; 18:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/89\">",
"      Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/90\">",
"      Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/91\">",
"      Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/92\">",
"      Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/93\">",
"      Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/94\">",
"      Mellors JW, Mu&ntilde;oz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/95\">",
"      Thi&eacute;baut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epid&eacute;miologie du SIDA en Aquitaine (GECSA). AIDS 2000; 14:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/96\">",
"      Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/97\">",
"      Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/98\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/99\">",
"      Yazdanpanah Y, Vray M, Meynard J, et al. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med 2007; 8:439.",
"     </a>",
"    </li>",
"    <li>",
"     Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5 (abstract 118). XVII International HIV Drug Resistance Conference. 2008. Sitges, Spain.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/101\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/102\">",
"      Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/103\">",
"      Gale HB, Gitterman SR, Hoffman HJ, et al. Is Frequent CD4+ T-Lymphocyte Count Monitoring Necessary for Persons With Counts &gt;=300 Cells/&mu;L and HIV-1 Suppression? Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/104\">",
"      Sax PE. Can We Break the Habit of Routine CD4 Monitoring in HIV Care? Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/105\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/106\">",
"      Mofenson LM, Centers for Disease Control and Prevention, U.S. Public Health Service Task Force. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/107\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/108\">",
"      Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/109\">",
"      Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/110\">",
"      Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/111\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/112\">",
"      Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/113\">",
"      Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/114\">",
"      Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/115\">",
"      Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/116\">",
"      Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2012; 7:CD007189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/117\">",
"      Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168.",
"     </a>",
"    </li>",
"    <li>",
"     MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women, November 2011. file://www.mtnstopshiv.org/node/3909 (Accessed on October 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/119\">",
"      Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/120\">",
"      Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/121\">",
"      Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/122\">",
"      Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/123\">",
"      Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/124\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/125\">",
"      Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med 2005; 352:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/126\">",
"      Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis 2007; 45 Suppl 4:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/127\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/128\">",
"      Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/129\">",
"      Samet JH, Freedberg KA, Savetsky JB, et al. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001; 15:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/130\">",
"      Mugavero MJ. Improving engagement in HIV care: what can we do? Top HIV Med 2008; 16:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/131\">",
"      Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/132\">",
"      Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/133\">",
"      Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002; 17:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/134\">",
"      Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004; 39:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/135\">",
"      Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS 2008; 22:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/136\">",
"      Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/12/29898/abstract/137\">",
"      Meyerson BE, Klinkenberg WD, Perkins DR, Laffoon BT. Who's in and who's out: use of primary medical care among people living with HIV. Am J Public Health 2007; 97:744.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3782 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29898=[""].join("\n");
var outline_f29_12_29898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY AND EARLY THERAPEUTIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prophylaxis against opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Zidovudine monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Two-drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMBINATION ANTIRETROVIRAL THERAPY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTIRETROVIRAL THERAPY AND OPPORTUNISTIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIRETROVIRAL THERAPY AND COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Liver-related morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HIV-associated nephropathy and end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - AIDS-defining malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Non-AIDS-defining malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4926281\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COSTS AND COST-EFFECTIVENESS OF ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OPTIMIZING THE EFFECTIVENESS OF ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ART AND HIV TRANSMISSION/PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevention of mother-to-child transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Discordant couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Preexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2256325\">",
"      Population studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      UPCOMING CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnostic testing and linkage to care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Adherence and retention in care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1396806388\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3782|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/57/5023\" title=\"figure 1\">",
"      AIDS case deaths 1985 2006",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/47/41726\" title=\"figure 2\">",
"      Stage of engagment in HIV care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_12_29899="Survival info DM";
var content_f29_12_29899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival information for diabetes self management education",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Skills",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Blood glucose monitoring",
"        </p>",
"        <p>",
"         &bull; Medication taking guidelines",
"        </p>",
"        <p>",
"         &bull; Mixing and injecting insulin, if required",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supplies",
"       </td>",
"       <td>",
"        <p>",
"         &bull; How to obtain necessary supplies and medication",
"        </p>",
"        <p>",
"         &bull; Guidelines for working with insurance plans",
"        </p>",
"        <p>",
"         &bull; Working with a pharmacist",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple pathophysiology",
"       </td>",
"       <td>",
"        <p>",
"         &bull; What is diabetes",
"        </p>",
"        <p>",
"         &bull; Diabetes risk factors",
"        </p>",
"        <p>",
"         &bull; Glycemic targets",
"        </p>",
"        <p>",
"         &bull; Balance of medication and exercise with nutrition and stress",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple meal planning",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Portion sizes",
"        </p>",
"        <p>",
"         &bull; Frequency of meals and snacks",
"        </p>",
"        <p>",
"         &bull; Composition of meals (carbohydrates, protein, fats)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SOS (emergency measures)",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Who to call for help",
"        </p>",
"        <p>",
"         &bull; When to call for help",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Dr. Barbara Schreiner.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29899=[""].join("\n");
var outline_f29_12_29899=null;
var title_f29_12_29900="AGAI management GERD 1";
var content_f29_12_29900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGAI management GERD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the efficacy of lifestyle modifications for GERD? Which elements should be recommended and in which circumstances?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Weight loss should be advised for overweight or obese patients with esophageal GERD syndromes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Elevation of the head of the bed for selected patients who are troubled with heartburn or regurgitation when recumbent. Other lifestyle modifications including, but not limited to, avoiding late meals, avoiding specific foods, or avoiding specific activities should be tailored to the circumstances of the individual patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Broadly advocating lifestyle changes for all (as opposed to selected) patients with GERD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        How do antisecretory therapies compare in efficacy and under what circumstances might one be preferable to another? What is an acceptable upper limit of empirical therapy in patients with suspected typical esophageal GERD syndromes before performing esophagogastroduodenoscopy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Antisecretory drugs for the treatment of patients with esophageal GERD syndromes (healing esophagitis, and symptomatic relief). In these uses, proton pump inhibitors (PPIs) are more effective than histamine2 receptor antagonists (H2RAs), which are more effective than placebo.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Twice-daily PPI therapy for patients with an esophageal syndrome with an inadequate symptom response to once-daily PPI therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. A short course or as-needed use of antisecretory drugs in patients with a symptomatic esophageal syndrome without esophagitis when symptom control is the primary objective. For a short course of therapy, PPIs are more effective than H2RAs, which are more effective than placebo.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Metoclopramide as monotherapy or adjunctive therapy in patients with esophageal or suspected extraesophageal GERD syndromes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29900=[""].join("\n");
var outline_f29_12_29900=null;
var title_f29_12_29901="FTT pathophysiologic causes";
var content_f29_12_29901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of failure to thrive, according to pathophysiologic mechanism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inadequate nutrient intake",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inappropriate feeding technique",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Disturbed caregiver/child relationship",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Economic deprivation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inappropriate nutrient intake (eg, excess fruit juice consumption, factitious food allergy, inappropriate preparation of formula, inadequate quantity of food, inappropriate food for age, neglect, food fads)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inappropriate parental knowledge of appropriate diet for infants and toddlers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Insufficient lactation in mother",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastroesophageal reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psychosocial problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal/infant dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mechanical problems (cleft palate, nasal obstruction, adenoidal hypertrophy, dental lesions)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sucking or swallowing dysfunction (CNS, neuromuscular, esophageal motility problems)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inadequate appetite or inability to eat large amounts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psychosocial problems &mdash; apathy or rumination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cardiopulmonary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypotonia, muscle weakness, or hypertonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anorexia of chronic infection or immune deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cerebral palsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CNS pathology (eg, tumor, hydrocephalus)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Genetic syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anemia (eg, iron deficiency)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic constipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastrointestinal disorder (eg, pain from gastroesophageal reflux, intestinal tract obstruction)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Craniofacial anomalies (eg, cleft lip and palate, micrognathia)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inadequate nutrient absorption or increased losses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malabsorption (lactose intolerance, cystic fibrosis, cardiac disease, malrotation, inflammatory bowel disease, milk allergy, parasites, celiac disease)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Biliary atresia, cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vomiting or \"spitting up\" (related to infectious gastroenteritis, increased intracranial pressure, adrenal insufficiency, or drugs [eg, purposeful administration of syrup of ipecac])",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intestinal tract obstruction (pyloric stenosis, hernia, malrotation, intussusception)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infectious diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Necrotizing enterocolitis or short bowel syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased nutrient requirements or ineffective utilization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic systemic disease (juvenile idiopathic arthritis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic or recurrent systemic infection (urinary tract infection, tuberculosis, toxoplasmosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic metabolic problems (hypercalcemia, storage diseases, and inborn errors of metabolism, such as galactosemia, methylmalonic acidemia, diabetes mellitus, adrenal insufficiency)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic respiratory insufficiency (bronchopulmonary dysplasia, cystic fibrosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Congenital or acquired heart disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29901=[""].join("\n");
var outline_f29_12_29901=null;
var title_f29_12_29902="Congenital CMV cranial CT";
var content_f29_12_29902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography: Intracranial calcifications in congenital cytomegalovirus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracranial&nbsp;computed tomography&nbsp;of an infant born with congenital&nbsp;cytomegalovirus disease and central nervous system involvement. Scan shows classic linear periventricular calcifications and&nbsp;cortical atrophy. The infant had microcephaly at birth and developmental disabilities and major motor impairment at eight years of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29902=[""].join("\n");
var outline_f29_12_29902=null;
var title_f29_12_29903="Inherited HHV-6 in an HCT recipient";
var content_f29_12_29903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    HHV-6 viral load kinetics in an allogeneic hematopoietic cell transplant recipient with inherited HHV-6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HHV-6 viral load in whole blood expressed as log",
"    <sub>",
"     10",
"    </sub>",
"    genomic equivalent copies per millileter of whole blood (",
"    <strong>",
"     X",
"    </strong>",
"    ) and as log",
"    <sub>",
"     10",
"    </sub>",
"    genomic equivalent copies/10",
"    <sup>",
"     6",
"    </sup>",
"    cells (",
"    <strong>",
"     &bull;",
"    </strong>",
"    ), leukocyte count (&loz;) and chimerism result in an allogeneic&nbsp;hematopoietic cell transplantation recipient.",
"    <div class=\"footnotes\">",
"     HHV-6: human herpesvirus 6",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jeulin H, Gu&eacute;ry M, Cl&eacute;ment L, et al. Chromosomally Integrated HHV-6: Slow Decrease of HHV-6 Viral Load After Hematopoietic Stem-Cell Transplantation. Transplantation 2009; 88:1142. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_12_29903=[""].join("\n");
var outline_f29_12_29903=null;
